Celltrion Pharm, Inc. (068760.KQ) Fundamentals
As of May 23, 2026
TL;DR — Celltrion Pharm, Inc. (068760.KQ) fundamentals as of May 23, 2026
Celltrion Pharm, Inc. (068760.KQ) trades at a trailing P/E of 63.2x and a P/B of 5.62x. Return on equity is 8.9%, return on invested capital is 7.0%, and the company carries a debt-to-equity ratio of 0.41. The current ratio sits at 1.66, free cash flow yield is 271.0%, and the dividend yield is 36.0%. PASS — clears all three quality screens.
For intrinsic value (DCF, owner earnings, Graham number) and the full 5-pillar score, see the 068760.KQ overview page.
Full Fundamentals Table
Every key indicator we track for 068760.KQ fundamentals, grouped by category. Industry median is shown where a sector classification is available.
| Metric | 068760.KQ | Healthcare median | What it measures |
|---|---|---|---|
| Revenue (TTM) | View full statement | - | Trailing twelve-month total revenue |
| Net Income (TTM) | View full statement | - | Bottom-line profit after taxes and interest |
| Free Cash Flow (TTM) | View full statement | - | Cash from operations minus CapEx |
| EPS (TTM) | N/A | - | Earnings per diluted share |
| ROE | 8.9% | 14% | Return on Equity — net income / shareholder equity |
| ROA | 5.1% | - | Return on Assets — net income / total assets |
| ROIC | 7.0% | - | Return on Invested Capital — NOPAT / (debt + equity) |
| P/E (Trailing) | 63.2x | 22x | Price / earnings — how many years of profit to recoup price |
| P/B | 5.62x | 3.8x | Price / book value — premium over net assets |
| P/S | 4.66x | - | Price / sales — useful when earnings are noisy |
| EV/EBITDA | 25.1x | - | Enterprise value / EBITDA — capital-structure neutral |
| Debt / Equity | 0.41 | 0.55 | Leverage — lower = less reliance on debt |
| Current Ratio | 1.66 | - | Current assets / current liabilities — short-term liquidity |
| Dividend Yield | 36.0% | - | Annual dividend / current price |
5-Year Trend
Indexed revenue growth path for 068760.KQ over the past five fiscal years (base = 100). Used as a quick sanity check on whether the top line is compounding or stalling.
Trend indexed from 1-year revenue growth rate. Full statement available in the analyst tier.
Industry Comparison
Across Healthcare, the median company prints P/E around 22x, P/B near 3.8x, ROE close to 14%, and a debt-to-equity ratio of 0.55. 068760.KQ's reading on each metric is in the ratio table above — anything materially above the median valuation multiple deserves a thesis to justify the premium, anything materially below the median return-on-capital flags an operational gap.
Compare 068760.KQ side-by-side with sector peers in the Healthcare stock list.
Quality Triple Check
Piotroski F-Score
Nine-point checklist for accounting quality and operational efficiency
7/9
PASS
Beneish M-Score
Earnings-manipulation detector — below -2.22 is healthy
-2.69
PASS
Altman Z-Score
Bankruptcy-risk model — above 2.99 is "safe zone"
6.16
PASS
Verdict: PASS — clears all three quality screens. Reasonable accounting hygiene, low manipulation risk, and bankruptcy-safe.
Next steps
- View the full 068760.KQ overview for intrinsic value (DCF), margin of safety, and the 5-pillar VM Score.
- Check the 068760.KQ beta page for volatility vs the S&P 500.
- Look at the 068760.KQ P/E ratio page for the 10-year valuation context.
- Dig into the 068760.KQ debt-to-equity page for leverage trends.
- Run your own model in the DCF calculator.
Frequently asked about 068760.KQ fundamentals
What are the key fundamentals for Celltrion Pharm, Inc. (068760.KQ)?↓
The core 068760.KQ fundamentals are P/E 63.2, ROE 8.9%, ROIC 7.0%, debt/equity 0.41, and dividend yield 36.0%. The complete ratio table on this page covers revenue, net income, FCF, EPS, ROA, P/B, P/S, EV/EBITDA, and current ratio.
How does 068760.KQ compare to its Healthcare peers?↓
The Healthcare sector median P/E is roughly 22x, ROE 14%, and D/E 0.55. 068760.KQ prints P/E 63.2, ROE 8.9%, and D/E 0.41. Use the Industry Comparison row in the ratio table for the full diff.
Does 068760.KQ pass the Quality Triple Check?↓
068760.KQ passes 3 of 3 quality screens (Piotroski F-Score, Beneish M-Score, Altman Z-Score). Detailed verdict above.
How is "fundamentals" different from intrinsic value?↓
Fundamentals describe what the business looks like today: profit, cash flow, leverage, returns on capital. Intrinsic value uses those fundamentals as inputs to a DCF (or similar model) and discounts the future cash flows back to today. Use both — fundamentals tell you whether a business is healthy, intrinsic value tells you whether the price is fair.
How often does ValueMarkers update 068760.KQ fundamentals?↓
Cached financial statements refresh every 12 hours. The ratio table on this page is rebuilt every 6 hours via Next.js ISR, and the underlying FMP data refreshes on each new earnings release.